Filing Flows › Pyxis Oncology (PYXS) › Q2 2025
Pyxis Oncology (PYXS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Pyxis Oncology (PYXS) reported revenue of $2.8M for the second quarter 2025 (Q2 2025). Operating margin was -700.4%, net loss $18.4M (650.9% of revenue).
Pyxis Oncology, Q2 2025: revenue $2.8M, operating margin -700.4%, net loss $18.4M, operating cash flow −$17.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | — | — |
| Operating profit | −$19.8M | — | — |
| Net earnings | −$18.4M | — | — |
| Operating cash flow | −$17.3M | — | — |
What changed
Revenue was $2.8M in Q2 2025.
Operating costs exceeded revenue by $19.8M, an operating margin of -700.4%. The quarter ended with a net loss of $18.4M.
Operating cash flow was −$17.3M. Non-cash charges added back $535K of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items used $2.5M.
Questions
What was Pyxis Oncology's revenue in the second quarter 2025?
Pyxis Oncology (PYXS) reported revenue of $2.8M for the second quarter 2025 (Q2 2025).
Was Pyxis Oncology profitable in the second quarter 2025?
Operating loss was $19.8M (-700.4% of revenue) and net loss $18.4M.
Source: Pyxis Oncology 10-Q on SEC EDGAR.